An enormous 'X' and 'V' will grace the moon's surface on July 2. Here's how to see them
The nights surrounding the first quarter moon phase on July 2 present a good opportunity to spot colossal 'X' and 'V' features emblazoned on the lunar surface.
This month's first quarter phase occurs at 11:41 p.m. EDT on July 2 (0341 GMT on July 3), at which time the right side of the half-lit lunar disk will be illuminated by direct sunlight from the perspective of viewers in the northern hemisphere on Earth.
At this time, the sun shines at such an angle to make it appear as if there is a gigantic 'V' and 'X' marking the barren lunar surface. This kind of phenomenon is referred to as a 'clair-obscur' effect and occurs when the interplay between light and shadow leads to the chance formation of familiar shapes on the moon's craggy terrain.
The lunar letters are visible for roughly four hours in the run-up to each first quarter moon phase and are at their most impressive when seen just on the 'night' side of the terminator, with their upper reaches kissed by the sun's light. Try and find the lunar 'X' and 'V' on the lunar disk at sunset on July 2 and be sure to keep checking back to see how these shapes evolve over time.
If you miss the letters on the night side of the terminator, there's no need to lose hope, as they'll continue to be visible for a brief period after they pass to the 'day side' of the moon.
The lunar X is an optical effect formed when sunlight strikes elevated rim sections of the Bianchini, Purbach and La Caille Craters around the first quarter moon phase, according to stargazing website EarthSky.org. The feature can be found around 25 degrees south of the lunar equator close to the terminator, which is the line separating the dayside and nightside of the moon, close to the prominent Werner and Aliacensis Craters.
To find the lunar 'V', moongazers must follow the line of the terminator up to a point less than 10 degrees above the lunar equator to find the partially shadowed form of the Ukert Crater. Both objects can be spotted through a small backyard telescope with a 6-inch aperture, though a larger scope will help resolve detail in the myriad craters and broken terrain dotting the surrounding moonscapes.
TOP TELESCOPE PICK
Want to see the lunar X and V? The Celestron NexStar 4SE is ideal for beginners wanting quality, reliable and quick views of celestial objects. For a more in-depth look at our Celestron NexStar 4SE review.
Stargazers interested in exploring the lunar surface should check out our guides to the best telescopes and binoculars available in 2025. Photographers interested in capturing the moon's surface should also read our roundup of the best cameras and lenses for astrophotography.
This article was updated at 3:10 a.m. EDT (0810 GMT) on July 2 to change 'June 2' to the correct date of 'July 2'.
Editor's Note: If you capture a picture of the letters on the moon and want to share it with Space.com's readers, then please send your photo(s), comments, and your name and location to spacephotos@space.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
24 minutes ago
- Associated Press
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax's GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique multi-antigen approach ATLANTA, GA - July 3, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant - commonly known as 'Nimbus' - spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a 'Variant Under Monitoring,' is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve. 'The emergence of the Nimbus variant is a stark reminder that we need 'smarter' vaccines, not just newer ones,' said David Dodd, Chairman and CEO of GeoVax. 'Our GEO-CM04S1 vaccine was designed for this purpose and is built to potentially provide broader and longer-lasting protection, especially for the immunocompromised patients most at risk.' GEO-CM04S1: Multi-Antigen Protection for the Immunocompromised Unlike mRNA vaccines that rely solely on the Spike protein, GEO-CM04S1 delivers both Spike (S) and Nucleocapsid (N) antigens, stimulating an immune response that includes not only an antibody response, but also robust T-cell activity. This is believed to be critical for cross-variant protection and extended durability, particularly in individuals with weakened immune systems. GEO-CM04S1 is currently being evaluated in two Phase 2 clinical trials, focused on populations at greatest risk from COVID-19 complications, including blood cancer patients scheduled to receive stem cell transplant therapy. In one of the ongoing Phase 2 trials, the mRNA control arm was discontinued due to poor immunogenicity with the remainder of the trial only including GEO-CM04S1 which surpassed the immunogenicity target, reinforcing the limitations of monovalent vaccines and the important value of a multi-antigen vaccine approach in such high-risk patient populations. 'There are more than 40 million immunocompromised individuals in the U.S. alone,' said Dodd. 'They are underserved by the current, FDA-approved vaccine options that deliver only an antibody response and require a better solution with both breadth and longevity of protection.' Public Vaccine Policy and Regulatory Changes Support Platform Diversification Recent guidance from the U.S. Food and Drug Administration (FDA) calls for diversified vaccine platforms and risk-based regulatory pathways. Additionally, the CDC's narrowed 2025–2026 booster recommendations - now focused on adults 65+ and immunocompromised individuals - closely mirror GeoVax's clinical strategy and target population. GEO-CM04S1 has been proposed under BARDA's Rapid Response Partnership Vehicle (RRPV) for surge manufacturing support and integration into long-term public health preparedness efforts. The proposal, 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines', was selected by the RRPV, pending funding availability. 'As public health moves toward more targeted, durable, and inclusive vaccination strategies, GEO-CM04S1 is positioned to deliver where first generation COVID-19 vaccines fall short,' Dodd added. In addition to targeting today's variants, GEO-CM04S1 is structurally designed to adapt to future mutations and serve as a platform for multi-pathogen preparedness. As part of GeoVax's broader MVA-based portfolio, the platform underpins vaccine candidates for Mpox, smallpox, and hemorrhagic fever viruses, offering scale and flexibility across infectious disease threats. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]
Washington Post
an hour ago
- Washington Post
Rare object from beyond our solar system spotted zipping around Earth
A newly discovered interstellar object is hurtling around us, only the third such interloper to be observed in our solar system. The object is not expected to pose an impact risk to Earth, but telescopes around the world have been able to detect the mystery visitor. The object — provisionally known as A11pl3Z — gained attention on Tuesday when it was spotted by telescopes for NASA's early warning system for asteroid impacts. Shortly after the discovery, amateur and professional astronomers looked through archival images and found it in earlier data from June. More than 100 observations have been made of the object, including from telescopes in Chile and Arizona. The object is traveling fast, speeding at our solar system at about 245,000 kilometers per hour relative to the sub, according to astronomer Josep M. Trigo Rodríguez. It is currently located just inside the orbit of Jupiter. The object — which will get a new name when it is approved and published by the Minor Planet Center — is currently 528 million kilometers from Earth (roughly the the distance it would take to travel from Earth to the moon 1,370 times.) It's uncertain if the object — appearing very faint at the moment — is a comet or asteroid at this time, according to scientists on Minor Planet mailing list. But the observations so far have helped track the object's journey, indicating it likely came from outside of the solar system from a thin galactic disk. The object could between 12 miles (20 kilometers) to 25 miles (40 kilometers) wide, according to various scientists. Marshall Eubanks, chief scientist at Space Initiatives Inc., estimated it could come close enough to Mars in early October to be observed by the Mars Reconnaissance Orbiter, although it would be only about 0.2 pixels wide. It is expected to reach its closest point to the sun later around October 29, reaching a distance about twice as far as Earth is from the sun. This is the third interstellar object to be observed in our solar system, with the other two found in the past decade. In 2017, scientists observed the first interstellar object known as Oumuamua, appearing rocky and cigar-shaped. Although it puzzled scientists because it didn't quite fit the definition of an asteroid or comet. In 2019, scientists saw our second interstellar visitor, comet 2I/Borisov. Part of the recent discoveries may be chalked up to more observations over time and a significantly improved capability to scan the skies, scientists said on the list serv. Such discoveries may become more commonplace with the surveys from the Vera Rubin Observatory, which has already found thousands of new asteroids in just 10 hours of operation. Compared to the other two previously found objects, A11pl3Z has a unique orbit. It has a very extreme hyperbolic trajectory through the solar system (or a high eccentricity) — meaning it won't be coming back to our solar system once it leaves. More observations will help scientists determine the object's path through our solar system, where it came from and if it's a comet. The object will appear brighter as it approaches Earth, but models show it will likely be on the other side of the sun. But, don't be bummed, there's probably another interstellar object waiting to be discovered in time.
TechCrunch
an hour ago
- TechCrunch
Israeli quantum startup Qedma just raised $26 million, with IBM joining in
Despite their imposing presence, quantum computers are delicate beasts, and their errors are among the main bottlenecks that the quantum computing community is actively working to address. Failing this, promising applications in finance, drug discovery, and materials science may never become real. That's the reason why Google touted the error correction capacities of its latest quantum computing chip, Willow. And IBM is both working on delivering its own 'fault-tolerant' quantum computer by 2029 and collaborating with partners like Qedma, an Israeli startup in which it also invested, as TechCrunch learned exclusively. While most efforts focus on hardware, Qedma specializes in error mitigation software. Its main piece of software, QESEM, or quantum error suppression and error mitigation, analyzes noise patterns to suppress some classes of errors while the algorithm is running and mitigate others in post-processing. Qedma's co-founder and chief scientific officer, Professor Dorit Aharonov, once described as a member of 'quantum royalty' for her and her father's contributions to the field, said this enables quantum circuits up to 1,000 times larger to run accurately on today's hardware, without waiting for further advancements on error correction at the computer level. IBM itself does both quantum hardware and software, and some of its partners, like French startup Pasqal, also develop their own hardware. But it sees value as well in partnering with companies more narrowly focusing on the software layer, like Qedma and Tiger Global-backed Finnish startup Algorithmiq, its VP of Quantum, Jay Gambetta, told TechCrunch. That's because IBM thinks driving quantum further requires a community effort. 'If we all work together, I do think it's possible that we will get scientific accepted definitions of quantum advantage in the near future, and I hope that we can then turn them into more applied use cases that will grow the industry,' Gambetta said. 'Quantum advantage' usually refers to demonstrating the usefulness of quantum over classical computers. 'But useful is a very subjective term,' Gambetta said. In all likelihood, it will first apply to an academic problem, not a practical one. In this context, it may take more than one attempt to build consensus that it's not just another artificial or overly constrained scenario. Techcrunch event Save $450 on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $450 on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW Still, having a quantum computer execute a program that a classical computer can't simulate with the same accuracy would be an important step for the industry — and Qedma claims it is getting closer. 'It's possible that already within this year, we'll be able to demonstrate with confidence that the quantum advantage is here,' CEO and co-founder Asif Sinay said. With a doctorate in physics, Sinay previously worked as a physicist at Magic Leap, then a multi-billion-worth AR company with a large R&D center in Israel. Like the founders of several Israeli startups, from Metacafe to Wiz, he is also a Talpion — an alum from Israel's elite military program Talpiot, where one of his classmates was Lior Litwak. Litwak is now a managing partner at Israeli VC firm Glilot Capital Partners, which led Qedma's $26 million Series A through its early growth fund, Glilot+, which he heads. The round included participation from existing investors such as TPY Capital, which backed Qedma's $4.7 million seed round in 2020, as well as new investors including Korean Investment Partners — and IBM. Since last September, Qedma has been available through IBM's Qiskit Functions Catalog, which makes quantum more accessible to end users. Sinay noted the synergies between the two companies, but emphasized that Qedma's plans are hardware-agnostic. The startup has already conducted a demo on the Aria computer from IonQ, a publicly listed U.S. company focused on trapped ion quantum computing. In addition, Qedma has an evaluation agreement with an unnamed partner Sinay described as 'the largest company in the market.' Recently, it also presented its collaboration with Japan's RIKEN on how to combine quantum with supercomputers. Image Credits:Qedma The joint Q2B Tokyo presentation was co-delivered by Qedma's CTO and third co-founder, Professor Netanel Lindner. An associate professor of theoretical physics and research group lead at Technion, he told TechCrunch he is hoping that some of his former doctorate students — or others they know — will join Qedma as part of the startup's hiring efforts. According to Sinay, Qedma will use the proceeds from its latest funding round to grow its team from around 40 to between 50 and 60 people. Some of these new recruits will be researchers and software engineers, but he said the startup also plans to hire for marketing and sales roles. 'We are selling our software to the end users, and our partners are the hardware manufacturers.' For hardware manufacturers like IBM, this software layer addresses the fact that a quant at a bank or a chemist who could leverage quantum are not experts in how to run circuits in the presence of noise. However, they know their respective domains and the conditions they want to set. 'So you want to be able to write the problem and say, I want it to run with this accuracy, I'm OK with this much usage of a quantum computer, and this much usage of a classical computer,' Gambetta said. 'They want [these] to be essentially little options that they can put into their software; and that's exactly what Qedma is doing, as well as some of [the] other partners we're working with.' Some researchers are already taking advantage of this via Qiskit Functions, or through partnerships that research institutions have established with Qedma and its industry peers. But the debate is still open as to when these experiments will become larger, and when quantum advantage will materialize for the broader world. Qedma hopes to accelerate the timeline by providing a shortcut. Unlike error correction at the computer level, which adds overhead that limits scalability, Qedma's approach doesn't require more quantum bits, or qubits. 'Our claim is that we can get quantum advantage even before a million qubits are achieved,' Lindner said. However, other companies are approaching that issue from different angles. For instance, French startup Alice & Bob raised $104 million earlier this year to develop a fault-tolerant quantum computer whose architecture relies on 'cat qubits,' which are inherently protected against certain errors, reducing the need for more qubits. But Qedma is not dismissive of the race for more qubits; since it acts as a booster either way, its team wants hardware to have as many qubits as possible, and the best qubits possible. In practice, though, it will be hard to maximize both at once, just like software-based error mitigation typically means longer runtimes. The best choice will depend on the specific task — but first, quantum will have to get to those tasks.
